Product Description
DS-7423 is a novel inhibitor of PI3K/mTOR and has demonstrated anticancer activity in several types of human tumor xenograft models.
Mechanisms of Action: PI3K Inhibitor, mTOR Inhibitor Binder
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Daiichi Sankyo
Company Location:
Company Founding Year: 2005
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Oncology Solid Tumor Unspecified|Endometrial Cancer|Colorectal Cancer
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
JapicCTI-121766 |
JapicCTI-121766 | P1 |
Completed |
Oncology Solid Tumor Unspecified |
2015-03-31 |
|||
NCT01364844 |
DS7423-A-U101 | P1 |
Completed |
Colorectal Cancer|Endometrial Cancer |
2013-11-01 |
2024-02-16 |
Recent News Events
Date |
Type |
Title |
|---|